查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球子宮內膜異位症市場預測（2022-2028）
市場調查報告書
商品編碼
1123173

全球子宮內膜異位症市場預測（2022-2028）

Global Endometriosis Market Research and Forecast 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 100 Pages | 商品交期: 2-3個工作天內

價格

全球子宮內膜異位症市場規模預計在預測期內（2021-2027 年）將以 3.0% 的巨大復合年增長率增長。

推動市場增長的因素包括女性育齡人口的增加、發達國家和新興國家對該疾病的認識提高，以及政府當局對子宮內膜異位症研究和開發的高投入等。此外，增加該領域的研究活動也在市場增長中發揮著重要作用。然而，欠發達經濟體缺乏熟練勞動力、先進療法成本高、新藥開發投資高、無創診斷測試不可用、疾病診斷緩慢等是阻礙市場增長的製約因素。

本報告研究和分析全球子宮內膜異位症市場，提供系統信息，包括市場概況、按細分市場和地區劃分的市場分析、競爭格局和公司概況。

內容

第 1 章報告概述

第 2 章市場概述和洞察

  • 調查範圍
  • 分析師見解和當前市場趨勢

第 3 章競爭格局

  • 主要公司分析
    • 雅培實驗室
    • 艾伯維公司
    • Myovant Sciences GmbH
    • 輝瑞公司
    • 武田製藥株式會社
  • 關鍵戰略分析
  • COVID-19 對主要公司的影響

第 4 章市場決定因素

  • 驅動程序
  • 限制因素
  • 機會

第 5 章市場細分

  • 按藥物類型劃分的全球子宮內膜異位症市場
    • 促性腺激素釋放激素激動劑
    • 非甾體抗炎藥
    • 孕激素
    • 口服避孕藥
  • 全球子宮內膜異位症市場：按診斷
    • 超聲波
    • 陰道檢查
    • 腹腔鏡檢查
    • 磁共振成像 (MRI)
    • 宮腔鏡檢查
    • 子宮超聲造影
  • 全球子宮內膜異位症市場：按治療
    • 激素療法
    • 疼痛管理
  • 全球子宮內膜異位症市場：按分銷渠道
    • 醫院
    • 藥店
    • 零售藥房
    • 郵購藥房
    • 電子商務

第六章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 世界其他地區

第七章公司簡介

  • Allergen PLC
  • Addex Therapeutics
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Debiopharm International SA
  • Evestra Inc.
  • Ipsen Pharma
  • Johnson & Johnson Services Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Neurocrine Biosciences, Inc.
  • ObsEva SA
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • ValiRx PLC
Product Code: OMR2018288

Global Endometriosis Market Size, Share & Trends Analysis Report By Drug Type (Gonadotropins Releasing Hormone Agonists, Non-Steroidal Anti-Inflammatory Drug, Progestin, and Oral Contraceptive Pills), By Diagnosis (Ultrasound, Pelvic Exam, Laparoscopy, Magnetic Resonance Imaging (MRI), Hysteroscopy, and Sonohysterography), By Treatment (Hormonal Therapy and Pain Management), By Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies, Mail Order Pharmacies, and E-Commerce) Forecast, 2021-2027

The endometriosis market is growing at a considerable CAGR of 3.0% during the forecast period (2021-2027). The factors that augment the growth of the market include a rise in the female reproductive population, a growing awareness of the disease in the developed and emerging economies, and high investment made by government authorities in the R&D of endometriosis disorders. Moreover, increasing researches in this field also play a vital role in the growth of the market. For instance, World Health Organization aims to support policies and services for endometriosis and collaborates with several civil society and endometriosis patient support groups. However, unavailability of a skilled workforce in the undeveloped economies, high cost of advanced therapeutic drugs, high investment for the development of novel drugs, lack of non-invasive diagnostic tests available and the time required for diagnosing the disease are some of the constraints that are estimated to challenge the growth of the market.

Further, high-cost hormone-based therapies dominate the market, and they play an important role in the patient's endometriosis treatment. As a result, players such as Bayer AG and AbbVie, Inc. offer patient assistance programs to assist patients to decrease their out-of-pocket expenses. Patient access to patient assistance programs for costly prescriptions is likely to increase patient adherence to these treatments, driving the market over the forecast period. Moreover, a lack of awareness among people is also estimated to hinder market growth. For instance, according to the analysis of Endometriosis UK, around 62% of women between the ages of 16-54 years delay their treatment as they think the symptoms are not serious or don't treat due to embarrassment. Conversely, technological advancement in the field by research institutes for the treatment of endometriosis disease and supportive government regulations are some of the opportunities that are estimated for the market players.

Impact of COVID-19 on the Global Endometriosis Market

The global endometriosis market is hardly hit by the COVID-19 pandemic since December 2019. The outbreak of COVID-19 in the major economies has disrupted the diagnosis of endometrioses disease across the globe which resulted in the decrease of market share. This was mainly due to the lockdowns imposed by the governments and only the emergency diagnosis was allowed as the priority was given to the patients suffering from COVID-19. There was a postponement of planned surgical or fertility treatments and an eventual increase in the waitlist for services being observed.

Segmental Outlook

The global endometriosis market is segmented based on drug type, diagnosis, treatment, and distribution channel. Based on the drug type segment, the market is segmented into gonadotropins releasing hormone agonists, non-steroidal anti-inflammatory drugs, progestin, and oral contraceptive pills. Based on the diagnosis segment, the market is segmented into ultrasound, pelvic exam, laparoscopy, magnetic resonance imaging (MRI), hysteroscopy, and sonohysterography. Based on the treatment segment, the market is segmented into hormonal therapy and pain management. Further, based on the distribution channel segment, the market is bifurcated into hospital pharmacies, drug stores, retail pharmacies, mail-order pharmacies, and e-commerce.

Global Endometriosis Market Share by Diagnosis, 2020 (%)

Global Endometriosis Market Share by Diagnosis

Pelvic Exam Segment to Hold a Lucrative Share in the Global Endometriosis market

Amongst the diagnosis type segment of the global endometriosis market, the pelvic exam segment was estimated to have one of the largest shares in the diagnosis segment for the endometriosis market. The pelvic exam is carried out manually by the doctor for checking the size of the ovaries and uterus and noting any tender areas or unusual growths. Besides, the laparoscopy segment also had a significant contribution to the growth of the market. The ability of this surgery to effectively diagnose endometriosis and even remove it in mild-moderate cases with only a minor incision has led to increased demand and revenue. Increasing adoption of minimally invasive surgeries and growth in healthcare infrastructure with technological advancement are some of the factors that promote the growth of the laparoscopy market. This is performed by placing a video camera through the trocar and is used to see the inside and abdomen of a patient.

Regional Outlooks

The global endometriosis market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America (the US and Canada), Europe (Germany, Spain, Italy, France, the UK, and the Rest of Europe), Asia-Pacific (India, China, Japan South Korea, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East and Africa, and Latin America). North America region is estimated to have one of the largest shares in this market. The high prevalence of the female population suffering from endometriosis disease, high awareness among people regarding health issues, high healthcare infrastructure, and availability of prominent market players are some of the factors that drive the growth of the market in this region. Europe is also estimated to have a significant contribution owing to the presence of refined healthcare infrastructure.

Endometriosis Market, by Region 2021-2027

Endometriosis Market, by Region

Asia-Pacific is projected to highest Contributor to the growth of the Global Endometriosis market

Asia-Pacific is estimated to be one of the fastest-growing regions owing to the rise in the number of generic manufacturers and the increase in the prevalence of endometriosis disease with the rise in population in emerging economies like China and India. Besides, the region's rapid growth is due to continued advancements in healthcare technologies and increased awareness of women's health.

Market Player Outlook

Key players of the endometriosis market include Abbott Laboratories, AbbVie Inc., Bayer AG, AstraZeneca plc, Pfizer Inc., Takeda Pharmaceutical Company Ltd., Neurocrine Biosciences, Inc., and Sanofi S.A, among others. To survive in the market these players adopt different marketing strategies such as a merger, acquisitions, product launch, and geographical expansion so on. For instance, in May 2020, AbbVie completed the acquisition of Allergan plc $193.23 per Allergan share to increase the company's therapeutic categories.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global endometriosis market based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Endometriosis Market Industry
  • Recovery Scenario of Global Endometriosis Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Abbott Laboratories
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. AbbVie, Inc.
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Myovant Sciences GmbH
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Pfizer, Inc.
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
    • 3.1.5. Takeda Pharmaceutical Company Ltd.
      • 3.1.5.1. Overview
      • 3.1.5.2. Financial Analysis
      • 3.1.5.3. SWOT Analysis
      • 3.1.5.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Endometriosis Market by Drug Type
    • 5.1.1. Gonadotropins Releasing Hormone Agonists
    • 5.1.2. Non-Steroidal Anti-Inflammatory Drug
    • 5.1.3. Progestin
    • 5.1.4. Oral Contraceptive Pills
  • 5.2. Global Endometriosis Market by Diagnosis
    • 5.2.1. Ultrasound
    • 5.2.2. Pelvic Exam
    • 5.2.3. Laparoscopy
    • 5.2.4. Magnetic Resonance Imaging (MRI)
    • 5.2.5. Hysteroscopy
    • 5.2.6. Sonohysterography
  • 5.3. Global Endometriosis Market by Treatment
    • 5.3.1. Hormonal Therapy
    • 5.3.2. Pain Management
  • 5.4. Global Endometriosis Market by Distribution Channel
    • 5.4.1. Hospital
    • 5.4.2. Drug Stores
    • 5.4.3. Retail Pharmacies
    • 5.4.4. Mail Order Pharmacies
    • 5.4.5. E-Commerce

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Allergen PLC
  • 7.2. Addex Therapeutics
  • 7.3. Astellas Pharma Inc.
  • 7.4. AstraZeneca plc
  • 7.5. Bayer AG
  • 7.6. Debiopharm International SA
  • 7.7. Evestra Inc.
  • 7.8. Ipsen Pharma
  • 7.9. Johnson & Johnson Services Inc.
  • 7.10. Kissei Pharmaceutical Co., Ltd.
  • 7.11. Neurocrine Biosciences, Inc.
  • 7.12. ObsEva SA
  • 7.13. Sanofi S.A.
  • 7.14. Teva Pharmaceutical Industries Ltd.
  • 7.15. ValiRx PLC

LIST OF TABLES

  • 1. GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 3. GLOBAL GONADOTROPINS RELEASING HORMONE AGONISTS FOR ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUG FOR ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL PROGESTIN FOR ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL ORAL CONTRACEPTIVE PILLS FOR ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL ULTRASOUND IN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL PELVIC EXAM IN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL LAPAROSCOPY IN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) IN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL HYSTEROSCOPY IN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL SONOHYSTEROGRAPHY IN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 15. GLOBAL HORMONAL THERAPY FOR ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL PAIN MANAGEMENT FOR ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 17. GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 18. GLOBAL ENDOMETRIOSIS IN HOSPITAL MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 19. GLOBAL ENDOMETRIOSIS IN DRUG STORES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 20. GLOBAL ENDOMETRIOSIS IN RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 21. GLOBAL ENDOMETRIOSIS IN MAIL-ORDER PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 22. GLOBAL ENDOMETRIOSIS IN E-COMMERCE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 23. GLOBAL ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 24. NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 25. NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 26. NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 27. NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 28. NORTH AMERICAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 29. EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 30. EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 31. EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 32. EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 33. EUROPEAN ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 34. ASIA-PACIFIC ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 35. ASIA-PACIFIC ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 36. ASIA-PACIFIC ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 37. ASIA-PACIFIC ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 38. ASIA-PACIFIC ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 39. REST OF THE WORLD ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 40. REST OF THE WORLD ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 41. REST OF THE WORLD ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 42. REST OF THE WORLD ENDOMETRIOSIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL ENDOMETRIOSIS MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL ENDOMETRIOSIS MARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL ENDOMETRIOSIS MARKET, 2021-2027 (%)
  • 4. GLOBAL ENDOMETRIOSIS MARKET SHARE BY DRUG TYPE, 2020 VS 2027 (%)
  • 5. GLOBAL ENDOMETRIOSIS MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
  • 6. GLOBAL ENDOMETRIOSIS MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
  • 7. GLOBAL ENDOMETRIOSIS MARKET SHARE BY DISTRIBUTION CHANNEL, 2020 VS 2027 (%)
  • 8. GLOBAL GONADOTROPINS RELEASING HORMONE AGONISTS FOR ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUG FOR ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL PROGESTIN FOR ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL ORAL CONTRACEPTIVE PILLS FOR ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL ULTRASOUND IN ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL PELVIC EXAM IN ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL LAPAROSCOPY IN ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 15. GLOBAL MAGNETIC RESONANCE IMAGING (MRI) IN ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 16. GLOBAL HYSTEROSCOPY IN ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 17. GLOBAL SONOHYSTEROGRAPHY IN ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 18. GLOBAL HORMONAL THERAPY FOR ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 19. GLOBAL PAIN MANAGEMENT FOR ENDOMETRIOSIS MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 20. GLOBALENDOMETRIOSIS IN HOSPITAL MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 21. GLOBAL ENDOMETRIOSIS IN DRUG STORES MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 22. GLOBAL ENDOMETRIOSIS IN RETAIL PHARMACIES MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 23. GLOBAL ENDOMETRIOSIS IN MAIL-ORDER PHARMACIES MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 24. GLOBAL ENDOMETRIOSIS IN E-COMMERCE MARKET SHARE BY REGION, 2020 VS 2027 (%)
  • 25. US ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. CANADA ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. UK ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. FRANCE ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. GERMANY ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. ITALY ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. SPAIN ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. ROE ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 33. INDIA ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 34. CHINA ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 35. JAPAN ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 36. ROAPAC ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 37. REST OF THE WORLD ENDOMETRIOSIS MARKET SIZE, 2020-2027 ($ MILLION)